Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 3/20 | 0.45 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.40 |
| ▸ | PTPRS | Q13332 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14027112 | 0.85 | RPS6KB2 (0.53) | RPS6KB2ERN1TMIGD3ADORA2AADORA1 | |
| SCHEMBL2782222 | 0.83 | NPC1 (0.46) | RPS6KB2ERN1ADORA2AADORA1TNFRSF1A | |
| SCHEMBL6067845 | 0.81 | RPS6KB2 (0.55) | RPS6KB2ERN1TMIGD3ADORA2AADORA1 | |
| SCHEMBL6764756 | 0.81 | MAPT (0.45) | RPS6KB2ERN1TMIGD3ADORA2AADORA1 | |
| SCHEMBL6764775 | 0.78 | MAPT (0.46) | RPS6KB2ERN1TMIGD3ADORA2AADORA1 | |
| SCHEMBL7157852 | 0.77 | ESR1 (0.57) | RPS6KB2ERN1TMIGD3ADORA2AADORA1 | |
| SCHEMBL6068015 | 0.74 | TMIGD3 (0.45) | RPS6KB2ERN1TMIGD3ADORA2AADORA1 | |
| SCHEMBL6068194 | 0.74 | RPS6KB2 (0.44) | RPS6KB2ERN1TMIGD3ADORA2AADORA1 | |
| SCHEMBL6068037 | 0.74 | MAPT (0.45) | RPS6KB2ERN1TMIGD3ADORA2AADORA1 | |
| SCHEMBL6067982 | 0.73 | MAPT (0.47) | RPS6KB2ERN1TMIGD3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242633-A1 | Beta3 adrenergic agonists | EVERS BRITTA (DE) | 2004-12-02 | — | — | US | disclosed |
| US-6730792-B2 | PYRIDINE DERIVATIVES; ANTIDIABETIC, ANTICHOLESTEROL, AND ANTIINFLAMMATORY AGENTS; DECYCLIZATION, DEETHERIFICATION; OBESITY; RAISES HIGH DENSITY LIPOPROTEINS; LOWERS TRIGLYCERIDE LEVELS | ELI LILLY AND COMPANY | 2004-05-04 | — | — | US | disclosed |
| US-20030191156-A1 | Beta3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2003-10-09 | — | — | US | disclosed |
| CN-1441800-A | β3Adrenergic agonists | LILLY CO ELI (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1303509-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002006276-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191156-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | RPS6KB2 1918/4885ERN1 3643/4885TMIGD3 1757/4885 |
| US-20040242633-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | RPS6KB2 2103/4885ERN1 2827/4885TMIGD3 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.